bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023

Rhea-AI Summary

bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) will report its financial results for Q4 2022 on March 31, 2023, after market close. A conference call is scheduled for April 3, 2023, at 9:00 a.m. EDT to discuss these results. The company focuses on non-invasive cancer diagnostics and targeted treatments, highlighting its product CyPath® Lung, which is designed to detect early-stage lung cancer with high sensitivity and specificity. Future growth may depend on advancements in its therapeutic developments and the success of its revenue-generating products.

Positive

• The upcoming financial report could indicate potential growth or progress in the company's financial health.
• Focus on innovative cancer diagnostic solutions may enhance market positioning.

Negative

• The lack of specific financial metrics in the upcoming report could lead to uncertainty among investors.
• Forward-looking statements may create volatility if projections are not met or updated.

Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time

SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions.

Event:				bioAffinity Technologies Fourth Quarter 2022 Financial Results
Date:				Monday, April 3, 2023
Time:				9:00 a.m. EDT
Toll Free:				1-877-270-2148
International:				1-412-902-6510
Webcast:				Webcast link

A replay of the event will be available for 90 days at the webcast link above, which can also be found in the Investor Relations section of bioAffinity’s website at ir.bioaffinitytech.com.

About bioAffinity Technologies, Inc.

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230324005073/en/

bioAffinity Technologies

Julie Anne Overton

Director of Communications

jao@bioaffinitytech.com

LHA Investor Relations

Tirth T. Patel

tpatel@lhai.com

Source: bioAffinity Technologies, Inc.

FAQ

When will bioAffinity Technologies report Q4 2022 financial results?

bioAffinity Technologies will report its Q4 2022 financial results on March 31, 2023.

What time is the conference call for bioAffinity's Q4 2022 financial results?

The conference call is scheduled for April 3, 2023, at 9:00 a.m. EDT.

What is bioAffinity Technologies' main product for cancer diagnostics?

The main product is CyPath® Lung, a non-invasive test for early-stage lung cancer detection.

How can investors access bioAffinity’s earnings call?

Investors can access the earnings call via the webcast link provided in the press release.